1. 1) Schmid O. US Patent 2789981 (1957).
2. 2) Pateisky K. Treatment of myasthenia gravis pseudoparalytica; clinical testing and therapy with BC substances (BC40, BC47, BC48 and BC 51). Wien. Z. Nervenheilkd. Grenzgeb., 17, 53–84 (1959).
3. 3) Emeryk E, Wasowicz B. Evaluation of “Ubretid” (BC 51) in the treatment of myasthenia gravis. Neurol. Neurochir. Psychiatr. Pol., 13, 611–617 (1963).
4. 4) Ishigaki K, Murakami T, Ito Y, Yanagisawa A, Kodaira K, Shishikura K, Suzuki H, Hirayama Y, Osawa M. Treatment approach to congenital myasthenic syndrome in a patient with acetylcholine receptor deficiency. No To Hattatsu, 41, 37–42 (2009).
5. 5) Antimyasthenics. Martindale: the complete drug reference, 39th ed. (Brayfield A ed.) Pharmaceutical Press, London, pp. 694–700 (2017).